Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a, Open-Label Study to Evaluate the Safety and Efficacy of AR882 Administered Alone or in Combination With Febuxostat or Allopurinol in Gout Patients

Next Previous
Trial Profile

A Phase 2a, Open-Label Study to Evaluate the Safety and Efficacy of AR882 Administered Alone or in Combination With Febuxostat or Allopurinol in Gout Patients

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 23 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AR 882 (Primary) ; Allopurinol; Colchicine; Febuxostat; Oxipurinol
  • Indications Gout
  • Focus Pharmacodynamics; Proof of concept; Therapeutic Use
  • Sponsors Arthrosi Therapeutics Australia

Most Recent Events

  • 16 Oct 2023 According to an Arthrosi Therapeutics media release, company announced acceptance of poster presentations and oral presentation at the American College of Rheumatology (ACR) Convergence 2023 meeting, being held in San Diego, CA on November 10-15, 2023.
  • 05 Jun 2021 Results assessing pharmacokinetics and serum urate lowering effects of Ar882 in patients with Gout presented at the 22nd Annual Congress of the European League Against Rheumatism
  • 01 Jun 2021 According to an Arthrosi Therapeutics media release, results will be presented at the upcoming 2021 annual European Congress of Rheumatology (EULAR).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top